Get the Stockscreener App
110.33
0.42%
0.46
After Hours:
110.45
0.12
+0.11%
Monopar Therapeutics Inc stock is traded at $110.33, with a volume of 339.77K.
It is up +0.42% in the last 24 hours and up +25.83% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
See More
Previous Close:
$109.87
Open:
$110.29
24h Volume:
339.77K
Relative Volume:
1.82
Market Cap:
$739.11M
Revenue:
-
Net Income/Loss:
$-14.99M
P/E Ratio:
-53.39
EPS:
-2.0665
Net Cash Flow:
$-10.01M
1W Performance:
+4.18%
1M Performance:
+25.83%
6M Performance:
+56.96%
1Y Performance:
+145.34%
1-Day Range:
$106.34
$112.16
1-Week Range:
$101.00
$116.64
52-Week Range:
$29.18
$116.64
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
110.33 | 736.03M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Morgan Stanley | Overweight |
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Monopar Therapeutics Inc (MNPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Monopar Therapeutics Inc (MNPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Monopar Therapeutics Inc (MNPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Monopar Therapeutics Inc (MNPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MNPR|Monopar Therapeutics Inc|Price:110.450|Chg%:+0.580 - TradingKey
TradingKey - TradingKey
BTIG’s Mukherjee Initiates Buy on Monopar Therapeutics, Citing Emerging Head & Neck Cancer Data and Favorable Risk‑Reward Setup - TipRanks
MONOPAR THERAPEUTICS INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $125 FROM $105 - webull.com
Monopar Therapeutics Inc (MNPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why is Monopar Therapeutics stock down 7.6% today? - Traders Union
Monopar Therapeutics Inc. (MNPR) stock price, news, quote and history - Yahoo Finance UK
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $115 - Moomoo
H.C. Wainwright raises Monopar stock price target to $125 on NDA filing - Investing.com
Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125 - Moomoo
MNPR Maintained by HC Wainwright & Co. -- Price Target Raised to $125 - GuruFocus
Monopar Therapeutics (MNPR) Proxy Filing Summary - Quartr
Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125 - TipRanks
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $125 - Moomoo
Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease - Moomoo
Monopar Begins Rolling FDA NDA Submission for ALXN1840 - TipRanks
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease - The Manila Times
ALXN1840 Could Be First U.S. Wilson Therapy With Novel Mechanism in Decades - Stock Titan
Can leadership appointments spark further gains for Monopar Therapeutics stock? - Traders Union
Monopar adds commercial leaders ahead of drug filing By Investing.com - Investing.com Nigeria
Monopar Therapeutics stock slips below $105.4 support as weak price closes pressure momentum - Traders Union
MNPR stock draws attention as Monopar Therapeutics advances pipeline and reports recent financing me - Ad-hoc-news.de
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team - The Manila Times
Monopar adds commercial leaders ahead of drug filing - Investing.com
Press Release: Monopar Advances Launch Readiness With Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team - Moomoo
MNPR stock trades quietly as Monopar Therapeutics advances cancer pipeline - Ad-hoc-news.de
Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy) - Seeking Alpha
Cantor Fitzgerald reiterates Monopar stock Overweight rating at $109 By Investing.com - Investing.com South Africa
Monopar Therapeutics stock trades near $98.20–$111.48 range as buyer strength dominates session - Traders Union
Will Monopar Therapeutics stock regain momentum as buyers support the ongoing rally? - Traders Union
Price to sales forward of Monopar Therapeutics Inc – DUS:1IY0 - TradingView
Monopar Therapeutics stock drops almost 4% after earnings beat followed by downgrade to 'sell' - Traders Union
MNPR Q1 2026 Earnings: EPS Beats Estimates by 46% as Pipeline AdvancesEarnings Acceleration Picks - dars.gov.et
(MNPR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MNPR (MNPR): Arthur Klausner files Form 144/A to sell 5,000 shares - Stock Titan
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT - RTTNews
Monopar Therapeutics shares gain about 9.5% after immediate support holds above $100.45 - Traders Union
What's behind Monopar Therapeutics's latest 11.6% stock surge? - Traders Union
Form 144 Monopar Therapeutics Inc. For: 7 July By Investing.com - Investing.com Nigeria
[144] Monopar Therapeutics SEC Filing - Stock Titan
MNPR stock. Monopar Therapeutics stays tied to its clinical pipeline. - ad-hoc-news.de
Enterprise value to EBIT forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Monopar Therapeutics: ALXN1840's Bull Case Has Improved (NASDAQ:MNPR) - Seeking Alpha
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Monopar Therapeutics (MNPR) CFO nets shares from RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) CEO nets shares after RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) COO gains stock via RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):